Critical Outcome Technologies (COTQF) Stock Price, News & Analysis

Company Overview

Critical Outcome Technologies Inc. is a Canadian biotechnology company focused on the discovery and development of small-molecule therapies for cancer and other serious diseases. The company has used its drug-discovery platform to identify compounds intended to address molecular targets associated with treatment resistance and disease progression.

Its best-known product candidate is COTI-2, an orally administered anticancer compound designed to reactivate mutant p53, a tumor-suppressor protein commonly altered in cancer. The candidate has been studied in connection with cancers including ovarian cancer and head and neck squamous cell carcinoma. Critical Outcome Technologies has also reported research involving additional oncology compounds and potential applications in other disease areas.

The company was founded in Canada and has been based in London, Ontario. Its securities have historically traded in Canada and the United States under the symbols COT and COTQF, respectively. Public information about the company’s current operations, leadership, and development pipeline is limited, so its present corporate status and activities should be verified through recent regulatory filings.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 12/18/2013
• Today: 10/12/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:COTQF
• CIK: N/A
• Web: coti.theyatesnetwork.com
• Phone: (800) 798-8680
• Fax: 519-858-5179
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A